Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
728 studies found for:    lenalidomide
Show Display Options
Rank Status Study
1 Not yet recruiting Evaluation of the Immune Restoration Potential Of Lenalidomide
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Lenalidomide
2 Completed Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
3 Recruiting Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: Lenalidomide
4 Recruiting Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
Conditions: Leukemia, Myeloid;   Myelodysplastic Syndromes
Intervention: Drug: Lenalidomide
5 Completed Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: lenalidomide
6 Active, not recruiting Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Revlimid
7 Active, not recruiting Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
8 Completed
Has Results
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide
9 Active, not recruiting
Has Results
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
Condition: Adult T-Cell Leukemia-Lymphoma
Intervention: Drug: Lenalidomide
10 Completed
Has Results
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Condition: Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Interventions: Drug: Lenalidomide;   Drug: Recombinant human erythropoietin
11 Completed Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma
Condition: Hodgkin Disease
Intervention: Drug: Lenalidomide (Revlimid®)
12 Completed
Has Results
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
Conditions: AIDS-Related Kaposi Sarcoma;   Recurrent Kaposi Sarcoma
Intervention: Drug: Lenalidomide
13 Terminated
Has Results
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukaemia
Intervention: Drug: Lenalidomide
14 Active, not recruiting A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: panobinostat;   Drug: lenalidomide
15 Terminated LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
Condition: AML
Intervention: Drug: Lenalidomide
16 Recruiting Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission
Condition: Leukemia
Intervention: Drug: Lenalidomide
17 Active, not recruiting Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Conditions: Follicular Lymphoma;   Marginal Zone B-Cell Lymphoma;   MALT Lymphoma;   Lymphoma of Mucosa-Associated Lymphoid Tissue;   Lymphoma, Small Lymphocytic;   Waldenstrom Macroglobulinemia;   Mantle-Cell Lymphoma
Interventions: Drug: lenalidomide-low dose dexamethasone plus rituximab;   Drug: Lenalidomide + Rituximab
18 Active, not recruiting Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Lenalidomide
19 Completed
Has Results
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Condition: Non-Hodgkins Lymphoma
Intervention: Drug: Lenalidomide
20 Terminated
Has Results
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
Condition: T-cell Non-Hodgkin's Lymphoma
Intervention: Drug: Lenalidomide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.